28189379|t|Acute generalized exanthematous pustulosis secondary to levetiracetam and valproic acid use
28189379|a|Acute generalized exanthematous pustulosis (AGEP) is a rare cutaneous eruption characterized by the appearance of diffuse, sterile pustules on an erythematous and edematous base. Most cases are attributed to drug reactions, with antibiotics being the most common offending agents. Only a handful of case reports have described AGEP in the setting of antiepileptic use. Here, we report a case of AGEP secondary to dual antiepileptic therapy with levetiracetam and valproic acid in a 73-year- old female. The patient presented to the emergency department with the characteristic AGEP rash, fever, and leukocytosis. Upon discontinuation of the two medications and conservative management, the patient's symptoms quickly abated, and she was discharged from the hospital several days later.
28189379	0	42	Acute generalized exanthematous pustulosis	T047	C0877055
28189379	43	55	secondary to	T080	C0175668
28189379	56	69	levetiracetam	T109,T121	C0377265
28189379	74	87	valproic acid	T109	C0078004
28189379	88	91	use	T169	C0457083
28189379	92	134	Acute generalized exanthematous pustulosis	T047	C0877055
28189379	135	141	(AGEP)	T047	C0877055
28189379	147	151	rare	T080	C0522498
28189379	152	170	cutaneous eruption	T184	C0015230
28189379	171	184	characterized	T052	C1880022
28189379	192	202	appearance	T080	C0700364
28189379	206	213	diffuse	T082	C0205219
28189379	215	231	sterile pustules	T033	C4015236
28189379	238	250	erythematous	T047	C0041834
28189379	255	269	edematous base	T184	C0013604
28189379	300	314	drug reactions	T046	C0041755
28189379	321	332	antibiotics	T195	C0003232
28189379	348	354	common	T081	C0205214
28189379	355	371	offending agents	T120	C0450442
28189379	391	403	case reports	T170	C0085973
28189379	409	418	described	T078	C1552738
28189379	419	423	AGEP	T047	C0877055
28189379	442	455	antiepileptic	T121	C0003299
28189379	456	459	use	T169	C0457083
28189379	470	476	report	T170	C0684224
28189379	479	483	case	T077	C1706256
28189379	487	491	AGEP	T047	C0877055
28189379	492	504	secondary to	T080	C0175668
28189379	505	509	dual	T052	C1705764
28189379	510	523	antiepileptic	T121	C0003299
28189379	524	531	therapy	T061	C0087111
28189379	537	550	levetiracetam	T109,T121	C0377265
28189379	555	568	valproic acid	T109	C0078004
28189379	583	586	old	T098	C0001792
28189379	587	593	female	T032	C0086287
28189379	599	606	patient	T101	C0030705
28189379	624	644	emergency department	T073,T093	C0562508
28189379	654	668	characteristic	T080	C1521970
28189379	669	673	AGEP	T047	C0877055
28189379	674	678	rash	T184	C0015230
28189379	680	685	fever	T184	C0015967
28189379	691	703	leukocytosis	T046	C0023518
28189379	710	725	discontinuation	T033	C1444662
28189379	737	748	medications	T170	C4284232
28189379	753	776	conservative management	T061	C0459914
28189379	782	791	patient's	T101	C0030705
28189379	792	800	symptoms	T184	C1457887
28189379	801	808	quickly	T080	C0456962
28189379	809	815	abated	T052	C3853704
28189379	829	839	discharged	T058	C0030685
28189379	849	857	hospital	T073,T093	C0019994
28189379	858	870	several days	T033	C3845714